Patents by Inventor Jean-Francois Toussaint

Jean-Francois Toussaint has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGENIC COMBINATIONS
    Publication number: 20230390381
    Abstract: This disclosure provides immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent, e.g., co-localized, administration. More specifically, the respiratory pathogen is respiratory syncytial virus (RSV). This disclosure also concerns provides the use of such immunogenic combinations, and methods for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.
    Type: Application
    Filed: December 15, 2022
    Publication date: December 7, 2023
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Ann-Muriel STEFF, Jean-Francois TOUSSAINT, Alessandra VITELLI
  • Immunogenic combinations
    Patent number: 11571472
    Abstract: Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: February 7, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Ann-Muriel Steff, Jean-Francois Toussaint, Alessandra Vitelli
  • METHODS OF INDUCING AN IMMUNE RESPONSE
    Publication number: 20220184158
    Abstract: There is provided inter alia a method of treating cancer in a mammal, said method comprising the steps of: (i) administering to the mammal a first composition comprising an antigen or comprising a nucleic acid encoding an antigen and (ii) administering to the mammal a second composition comprising an oncolytic virus wherein the oncolytic virus comprises a nucleic acid encoding the antigen.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 16, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Jean-Francois TOUSSAINT, Vanesa BOL
  • IMMUNOGENIC COMBINATIONS
    Publication number: 20170143820
    Abstract: Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.
    Type: Application
    Filed: June 12, 2015
    Publication date: May 25, 2017
    Applicant: GLAXOSMITHKLINE SA
    Inventors: Ann-Muriel STEFF, Jean-Francois TOUSSAINT, Alessandra VITELLI
  • COMBINATION IMMUNOGENIC COMPOSITIONS
    Publication number: 20160193322
    Abstract: Combination immunogenic compositions capable of eliciting protection against both RSV and B. pertussis infection and disease are provided, including compositions which comprise a recombinant F protein analog of RSV, together with B. pertussis acellular (Pa) or whole cell (Pw) antigens.
    Type: Application
    Filed: August 4, 2014
    Publication date: July 7, 2016
    Inventors: Ann-Muriel STEFF, Stéphane T. TEMMERMAN, Jean-François TOUSSAINT
  • INACTIVATED DENGUE VIRUS VACCINE WITH ALUMINIUM-FREE ADJUVANT
    Publication number: 20160120972
    Abstract: The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.
    Type: Application
    Filed: January 11, 2016
    Publication date: May 5, 2016
    Inventors: Benoit BARAS, Dirk GHEYSEN, Isabelle Solange Lucie KNOTT, Jean-Paul PRIEELS, Jean-Francois TOUSSAINT
  • Inactivated dengue virus vaccine with aluminium-free adjuvant
    Patent number: 9265821
    Abstract: The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: February 23, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Benoit Baras, Dirk Gheysen, Isabelle Solange Lucie Knott, Jean-Paul Prieels, Jean-Francois Toussaint
  • METHOD FOR ELICITING IN INFANTS AN IMMUNE RESPONSE AGAINST RSV AND B. PERTUSSIS
    Publication number: 20150202283
    Abstract: This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) and Bordetella pertussis through maternal immunization using recombinant respiratory syncytial virus (RSV) and B. pertussis antigens to reduce the incidence or severity of RSV and pertussis infection in young infants.
    Type: Application
    Filed: August 5, 2013
    Publication date: July 23, 2015
    Inventors: Ann-Muriel Steff, Stephane T. Temmerman, Jean-Francois Toussaint
  • INACTIVATED DENGUE VIRUS VACCINE WITH ALUMINIUM-FREE ADJUVANT
    Publication number: 20110318407
    Abstract: The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.
    Type: Application
    Filed: February 16, 2010
    Publication date: December 29, 2011
    Inventors: Benoit Baras, Dirk Gheysen, Isabelle Solange Lucie Knott, Jean-Paul Prieels, Jean-Francois Toussaint